Lawsuit probes Boston Scientific over missed earnings and cybersecurity fallout

Pomerantz LLP is investigating Boston Scientific for potential securities fraud after the company missed Q3 2026 earnings estimates and lowered sales guidance due to a major cybersecurity incident and operational challenges. The stock dropped nearly 6% following the announcement. The investigation aims to determine if Boston Scientific and its executives engaged in unlawful business practices. Investors affected by this situation are encouraged to contact the law firm for possible class action participation.

Boston Scientific Corporation trades at USD 44.75 on Pluang as of Nov 11, 2026 06:21 WIB, showing a 1.66% gain in the last day. The stock's market cap is $63.81 billion with a 52-week low of $41.58. Despite recent challenges, typical hold time on Pluang is 83 days, and order activity leans 64% Sell and 36% Buy.